US committee backs terlipressin approval for HRS-1
HRS-1 is an acute and life-threatening syndrome with a survival time of just two weeks if left untreated
Read More
Tag: HRS-1
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
